Antibiotics transformed once-lethal procedures into routine interventions. Cesarean delivery, joint replacement, appendectomy—each depends not merely on technical precision but on...
Read moreOver the past several weeks, sustained policy attention has centered on Medicaid eligibility redeterminations, Medicare Advantage payment recalibration, and intensified...
Read moreIn the Calendar Year 2027 Medicare Advantage and Part D Advance Notice, the Centers for Medicare & Medicaid Services projected...
Read moreMedicaid policy shifts centered on work requirements and eligibility verification have returned to the foreground of federal and state health...
Read moreHouse oversight activity directed at health insurer practices and alleged exchange fraud has become a sustained focus of policy and...
Read moreIn early 2026, the U.S. Food and Drug Administration issued a refusal-to-file letter declining to review a major manufacturer’s biologics...
Read moreThe 340B Drug Pricing Program — long treated as stable plumbing inside safety‑net finance — has re‑entered active policy dispute...
Read moreThe legal architecture of women’s health has been redrawn faster than the clinical delivery system can respond. Search and social...
Read moreThe hospital can be clinically excellent, financially solvent, and fully accredited — and still be one phishing email away from...
Read moreData access is negotiated, not assumed Healthcare founders often treat data access as a partnership benefit. Institutions treat it as...
Read moreCoding is the first gate, not the last Without a billing code, revenue attribution is difficult. Without revenue attribution, purchasing...
Read moreThe most dangerous myth about medical artificial intelligence is that the decisive variable is intelligence. The decisive variable is governance:...
Read moreClinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read moreDaily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.
Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.
© 2026 Daily Remedy
© 2026 Daily Remedy